Back to top
more

Arcellx (ACLX)

(Delayed Data from NSDQ)

$72.08 USD

72.08
237,863

+0.94 (1.32%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $72.14 -0.05 (-0.06%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About Arcellx (ACLX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Arcellx (ACLX) stock based on the movements in the options market lately.

Zacks Equity Research

Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?

by Zacks Equity Research

Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Adobe's (ADBE) first-quarter fiscal 2023 results are expected to reflect gains from solid momentum across the Digital Media and Digital Experience segments.

Zacks Equity Research

Gilead's (GILD) Application for Trodelvy Gets EMA Validation

by Zacks Equity Research

Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.

Zacks Equity Research

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

by Zacks Equity Research

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Zacks Equity Research

Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology

by Zacks Equity Research

Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.

Zacks Equity Research

Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Arcellx, Inc. (ACLX) points to a 61.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.